Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.
Completed
Takeda
Phase 4
2009-03-01
The purpose of this study is to determine the efficacy of pioglitazone compared to
glibenclamide, once daily (QD), taken together with metformin and lifestyle modification in
type 2 diabetic subjects with cardiovascular disease.
The goal of this study is to compare two different thresholds for initiation of medical
treatment for GDM. Pregnant women diagnosed with GDM will be randomized to either start
pharmacotherapy when they have reached at least 20% or at least 40% of capillary blood
glucose (CBG) values above the target goal. The investigators hypothesize that a lower
threshold of 20% elevated CBG levels, compared to 40%, will lead to lower rates of obstetric
and medical complications.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
